– USA, DC – Otolith Labs, a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, announced the appointment of Raphael Michel to its Board as an independent Director.
About Raphael Michel
Raphael Michel has over 20 years of technology and business innovation experience and a proven track record of building industry-changing companies. He has received rigorous scientific and business training from top institutions like École Polytechnique (France), Stanford University, and UC Berkeley Haas. Raphael started as the first employee at Vessix Vascular (acquired by Boston Scientific), led the development and commercialization of a new medical robotic system at Hansen Medical (acquired by Auris Health), then co-founded Eargo, the first-ever hearing aid company to go public through an IPO in the US, leading it from inception through commercialization and raising $70 million in financing, and Onera Health, where he led an international team with the mission to democratize in-home diagnosis and management of chronic conditions. Most recently, he was working at Google’s X Labs.
The company also announced the appointment of Dan Wagner as Chief Commercial Officer
About Dan Wagner
Dan Wagner is spearheading Otolith’s go-to-market plan and will build out Otolith’s infrastructure related to downstream operations in market access, medical affairs, sales operations, and marketing. Otolith Labs’ technology is a head-worn wearable device being investigated for the treatment of vertigo episode symptoms associated with vestibular migraines. The headband device applies localized mechanical stimulation to the vestibular system through precisely calibrated vibrations. It is primarily intended for use by chronic vertigo patients, for whom there are limited treatment options.
Dan Wagner is a career medical device and biotechnology executive with more than 17 years of industry experience. Dan’s global experience has touched markets in over 60 countries and over a dozen healthcare specialties working with capital equipment, diagnostics, therapeutics, DME, and biologics. He has served in numerous leadership roles at Olympus Corporation, HeartSciences, Signature Biologics, and most recently as CCO at Spark Biomedical.
Throughout his career, Dan has led corporate growth objectives, defined business operations, and integrated strategy and data into a corporate cadence for success. Dan will develop Otolith’s strategic commercialization plan and build out the sales and marketing infrastructure.
About Otolith Labs
Otolith Labs is developing prescription medical devices for the treatment of vestibular disorders, conditions experienced by millions of Americans. Otolith’s patented technology, which received Breakthrough Device Designation from the FDA for the treatment of chronic vertigo, uses precisely tuned vibrations to interact with the acceleration sensors in the inner ear, mitigating the symptoms of vertigo. Otolith is conducting clinical trials to evaluate its technology as an immediate symptom-relief treatment for chronic vertigo associated with vestibular disorders.
For more information: https://otolithlabs.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
